GLYXAMBI 10/5MG

About

Glyxambi 10/5mg is a fixed-dose combination medication containing Empagliflozin (10mg) and Linagliptin (5mg), specifically designed to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, works by reducing glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the body's natural ability to lower blood glucose by increasing incretin hormone levels, which in turn boosts insulin release and reduces glucagon secretion. This synergistic dual mechanism not only effectively lowers blood glucose but also provides significant cardiovascular and renal benefits, making it a comprehensive treatment option.

Uses

• Improve glycemic control in adults with type 2 diabetes.
• Reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
• Reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease.
• As an adjunct to diet and exercise.

Directions For Use

Take one tablet orally once daily in the morning, with or without food, as directed by your physician.

Benefits

• Effectively lowers blood glucose levels.
• Reduces risk of cardiovascular death.
• Lowers risk of heart failure hospitalization.
• May promote modest weight loss.
• Offers renal protective effects.
• Improves overall glycemic control.

Side Effects

• Urinary tract infections (UTIs)
• Genital yeast infections
• Increased urination
• Nausea
• Diarrhea
• Headache
• Back pain
• Joint pain
• Hypoglycemia (when used with insulin/sulfonylurea)
• Thirst
• Dizziness
• Ketoacidosis (rare)

Safety Measures

• Alcohol - Limit alcohol intake as it can increase the risk of hypoglycemia and ketoacidosis, especially with SGLT2 inhibitors.
• Pregnancy - Not recommended during the second and third trimesters due to potential renal effects on the fetus. Consult your doctor.
• Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk. Consult your doctor.
• Liver - No dose adjustment is typically needed for mild to moderate hepatic impairment. Use with caution in severe cases.
• Kidney - Not recommended for patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) due to reduced efficacy and potential risks.
• Lung - No specific contraindications related to lung conditions, but monitor for respiratory symptoms if ketoacidosis is suspected.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.